Physician profile
Deborah E Smith
NPI 1598084170
$3,675.56
in general payments reported to CMS, 2019-2025
24 companies · $862 in 2025
The $862 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,088 · 2022: $693 · 2023: $458 · 2024: $575 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,894.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $971.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $813.56 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $546.09 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.75 | 2021-2023 | |
| Lilly USA, LLC | $154.74 | 2021-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.88 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $128.31 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $123.17 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.63 | 2021-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $79.24 | 2022-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $70.00 | 2022 | |
| Corcept Therapeutics | $66.89 | 2025 | Korlym |
| Boston Scientific Corporation | $52.75 | 2025 | Watchman Access System |
| Glaxosmithkline, LLC. | $44.21 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Cipher Pharmaceuticals US LLC | $39.02 | 2025 | Natroba, Spinosad |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $35.71 | 2023-2025 | Immunocap |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.46 | 2024 | Xifaxan, Trulance |
| Tris Pharma INC | $18.37 | 2024 | Dyanavel Xr |
| Biohaven Pharmaceuticals, INC. | $17.80 | 2021 | |
| Merck Sharp & Dohme LLC | $17.75 | 2025 | Gardasil 9, Capvaxive |
| Sanofi Pasteur INC. | $15.57 | 2025 | |
| Amgen INC. | $14.95 | 2025 | Otezla, Repatha |
| Dexcom, INC. | $14.88 | 2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $12.20 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.